Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytosorbents Cor (NQ: CTSO )

0.8917 +0.0117 (+1.33%)
Streaming Delayed Price Updated: 10:44 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytosorbents Cor

< Previous 1 2 3 4 Next >
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
From CytoSorbents
Via GlobeNewswire
Recap: CytoSorbents Q4 Earnings
Via Benzinga
A Preview Of CytoSorbents's Earnings
Via Benzinga
CTSO Stock Earnings: CytoSorbents Beats EPS, Misses Revenue for Q4 2023
CTSO stock results show that CytoSorbents beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
From CytoSorbents
Via GlobeNewswire
What To Know About HC Wainwright & Co.'s Downgrade of CytoSorbents
Via Benzinga
Recap: CytoSorbents Q3 Earnings
Via Benzinga
Earnings Scheduled For March 14, 2024
Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
CytoSorb Blood Purification Results in Statistically Significant Reductions in Multiple Organ Failure and Dysfunction 
From CytoSorbents
Via GlobeNewswire
CYTOSORBENTS ALERT: Bragar Eagel & Squire, P.C. is Investigating Cytosorbents Corporation on Behalf of Cytosorbents Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Gold Moves Lower; US Crude Stocks Decline Last Week
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.27% to 37,758.26 while the NASDAQ rose 0.17% to 15,124.90.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Crude Oil Down 1%; US Wholesale Inventories Fall In November
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points on Thursday. The Dow traded up 0.14% to 37,708.15 while the NASDAQ rose 0.19% to 15,127.17. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Dow Gains 50 Points; US Jobless Claims Rise To 218,000
U.S. stocks traded higher this morning, with the Dow Jones index gaining over 50 points on Thursday. Following the market opening Thursday, the Dow traded up 0.14% to 37,708.72 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering
Company insiders participated in the transaction with $435,000 of investment 
From CytoSorbents
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
CytoSorbents Reports Third Quarter 2023 Financial and Operational Results
Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data... 
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Report Third Quarter 2023 Operating and Financial Results
From CytoSorbents
Via GlobeNewswire
CytoSorbents to Present at the 8th Annual Dawson James Conference
From CytoSorbents
Via GlobeNewswire
CytoSorbents Highlights Upcoming Presentations at EACTS 2023: Focus on Antithrombotic Removal including the 2nd Analysis of the International STAR Registry
From CytoSorbents
Via GlobeNewswire
CytoSorbents Announces Kathleen P. Bloch To Resume as Full-Time Chief Financial Officer
From CytoSorbents
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.